| answer text |
<p>The Government is engaging the market on its requirements for products that would
enable Respiratory Syncytial Virus (RSV) programmes to be implemented for infants
and older adults, following advice from the Joint Committee on Vaccination and Immunisation
in 2023. A final decision on these programmes will be taken following the outcome
of this process. If any RSV programmes are agreed to, their implementation will be
announced to the public and health professionals in due course.</p><p>Whilst population
wide immunisation is not currently available, the Government is increasing efforts
to minimise the number of severe cases of RSV. This is currently done by a targeted
immunisation offer to those known to be at highest risk of severe complications. The
National Health Service has also published signs and symptoms of RSV, and advice on
when parents should bring their children to seek medical attention. The UK Health
Security Agency has also provided public health messaging on social, national, and
regional media, highlighting the signs and symptoms of RSV and the steps that can
be taken to reduce infections, including reducing risks to young children.</p>
|
|
